Recent News

CEO Corner - Thursday, June 13, 2019 iCubate is proud to be a part of ASM Microbe 2019. Many of us will be on site at the Moscone Center in San Francisco for this outstanding scientific conference. At ASM Microbe 2019, there are many ways to learn why iCubate is right for your lab. These include: 1) attend iCubate's workshop @ 1pm on Thursday, June 20th; 2) stop by booth 4241 at 1pm on Friday, June 21st to see how easy it is to use iCubate assays; 3) Wes Coleman will demonstrate operating the iCubate platform - or you can try it for yourself at 1pm on Saturday, June 22nd at booth 4241; and 4) on Sunday, June 23rd @ 1pm at booth 4241, join the discussion about the value iCubate brings to the clinical laboratory. Look forward to seeing you in San Francisco.   Carter Wells CEO, iCubate  

CEO Corner

SAN FRANCISCO, CA, June 13, 2019 - iCubate is proud to be a part of ASM Microbe 2019. Many of us will be on site at the Moscone Center in San Francisco for this outstanding scientific conference. At ASM Microbe 2019, there are many ways to learn why iCubate is right for your lab. These include: 1) attend iCubate's workshop @ 1pm on Thursday, June 20th; 2) stop by booth 4241 at 1pm on Friday, June 21st to see how easy it is to use iCubate assays; 3) Wes Coleman will demonstrate operating the iCubate platform - or you can ...
Read More

iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assays

NEW YORK (GenomeWeb) — iCubate said today that it has formed a joint venture with Wondfo Biotech to commercialize infectious disease molecular diagnostics in China. The joint venture — called Wondfo-iCubate Biotech — will develop assays using iCubate's amplicon-rescued multiplex PCR (arm-PCR) technology, which the company has said can amplify up to a quarter of a million unique targets in one reaction with high specificity and sensitivity. iCubate said that it signed a series of strategic cooperation agreements with Guangzhou-based Wondfo in late 2018 to set the stage for the establishment of Wondfo-iCubate Biotech, and that the joint venture has ...
Read More

iCubate® receives the 2019 NAITA Global Trade Award

HUNTSVILLE, AL, April 19, 2019 – The North Alabama International Trade Association announced Thursday that Huntsville molecular diagnostic firm iCubate® received the 2019 NAITA Global Trade Award at NAITA’s 36th Annual World Trade Day Luncheon. With international sales leading the way to increased market opportunities, iCubate® provides rapid, accurate and affordable syndromic testing for infectious diseases to clinical laboratories of all sizes, ensuring that care providers across the globe have the right tools to improve treatment and outcomes for their patients. iCubate®, an associate company at HudsonAlpha Institute for Biotechnology, was founded in 2009 by Jian Han, MD, PhD, who ...
Read More

iCubate® and Wondfo Biotech form joint venture to provide high performance infectious disease molecular diagnostics to China

Huntsville, Ala. – iCubate®, Inc. and Guangzhou Wondfo Biotechnology Co., Ltd. (Wondfo) formed the joint venture company, Guangzhou Wondfo iCubate Biotechnology Co., Ltd (Wondfo-iCubate Biotech). The strategic purpose of Wondfo-iCubate Biotech is to couple iCubate’s technology and portfolio of products with Wondfo’s commercial strength in multiple in vitro diagnostic areas and become a leader in China’s broad molecular diagnostics market. The joint venture will advance the commercialization, business development, research and development and production in China. “iCubate’s founder, Dr. Jian Han, and our team developed the technology and platform to dramatically improve the way people can identify and detect infectious diseases. Entering ...
Read More

iCubate® Presents New Product Information to South Central Association of Clinical Microbiology

Huntsville, Ala. March 21, 2019 – iCubate®, a provider of molecular diagnostic solutions for infectious disease detection, hosted a panel presentation at the South Central Association of Clinical Microbiology (SCACM) meeting in Sandusky, Ohio. The presentation titled, “A Clinical Perspective of the iCubate® Solution for Bloodstream Infection” was led by Paul A. Granato, PhD, DABMM, FAAM, director of microbiology at the Laboratory Alliance of Central New York in Syracuse, New York and Matthew Conover, PhD, molecular diagnostic assay developer at iCubate. Well attended by an engaged audience of clinical microbiologists from Ohio, Kentucky, Minnesota, Wisconsin, Indiana, Illinois, West Virginia and ...
Read More

Bacterial Test Well-Suited for Small, Medium Labs, Study Says

June 29, 2018 - NEW YORK (GenomeWeb) – Researchers from four clinical microbiology laboratories reported this month that the iC-GPC assay developed by Huntsville, Alabama-based iCubate is an accurate and reliable tool for the detection of the five most common gram-positive bacteria responsible for bloodstream infections. Additionally, the test detects the presence of the three clinically relevant antibiotic resistance markers specific to methicillin-resistant Staphylococcus and vancomycin-resistant Enterococcus, they noted. The firm's assay and system may be particularly suitable for use in small and medium laboratories that don't have the sophisticated technical staff or time to devote to run more technical and more expensive assays, ...
Read More

Following First FDA Approval for MDx Platform, iCubate Has Eye on Point-of-Care Market

August 30, 2017 - NEW YORK (GenomeWeb) – Having recently secured US Food and Drug Administration approval for its molecular testing platform and first test, the iC-GPC assay for gram-positive bacteria associated with bloodstream infections and antibiotic resistance markers, iCubate is already planning its next commercial assay. The Huntsville, Alabama-based spinout of the HudsonAlpha Institute of Biotechnology plans to tailor its next bloodstream infection product to a gram-negative bacteria detection and drug resistant genes, and believes this assay will be even more extensive than the gram-positive assay. Company founder and CSO Jian Han envisions a future where point-of-care testing using their upcoming devices ...
Read More

CAD Lays the Groundwork for iCubate’s DNA Testing Devices

September 24, 2018 - iCubate, according to the company’s website, is a molecular diagnostic company with a novel multiplex polymerase chain reaction (mPCR) technology. It is also an integrated platform for infectious disease diagnostics and research applications. The iC-Cassette. (Image courtesy of iCubate.) To shed light on what this all means, and to explain how the company designed this system, we spoke to James Bullington, chief technology officer (CTO) of LSINC to learn all about it. LSINC is a product development, engineering design and consultancy firm, which has been helping to design and produce iCubate’s products since 2008. After completing ...
Read More